Clinicopathologic features of advanced RET fusion-positive lung cancers and outcomes in comparison to other fusion-positive lung cancers

被引：0
|
作者：
Drilon, Alexander E. [1 ]
Hellmann, Matthew David [1 ]
Wang, Lu [1 ]
Cho, Eun Jung [1 ]
Ladanyi, Marc [1 ]
Rizvi, Naiyer A. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.8076
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8076
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers
    Gautschi, O.
    Subbiah, V
    Konda, B.
    Bauer, T.
    McCoach, C.
    Falchook, G.
    Takeda, M.
    Patel, J.
    Weiss, J.
    Peled, N.
    Bazhenova, L.
    Soldatenkova, V
    French, P.
    Drove, N.
    Drilon, A.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 12 - 12
  • [2] RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future
    Chen, Monica F.
    Repetto, Matteo
    Wilhelm, Clare
    Drilon, Alexander
    [J]. DRUGS, 2024, 84 (09) : 1035 - 1053
  • [3] Efficacy and safety of selpercatinib in RET fusion-positive cancers other than lung or thyroid cancers.
    Subbiah, Vivek
    Konda, Bhavana
    Bauer, Todd
    McCoach, Caroline
    Falchook, Gerald
    Takeda, Masayuki
    Patel, Jyoti
    Weiss, Jared
    Peled, Nir
    Bazhenova, Lyudmila
    Soldatenkova, Victoria
    French, Pearl
    Drove, Nora
    Gautschi, Oliver
    Drilon, Alexander
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [4] Genomics of early progression on selpercatinib in patients with RET fusion-positive lung cancers
    Chen, M. F.
    Rosen, E.
    Falcon, C.
    Repetto, M.
    Yang, S. R.
    Chang, J.
    Kris, M. G.
    Rekhtman, N.
    Donoghue, M.
    Drilon, A.
    [J]. ANNALS OF ONCOLOGY, 2023, 34
  • [5] Brain Metastases in Patients with Fusion-Positive Lung Cancers
    Sui, J. S.
    Chen, M. F.
    Wilcox, J.
    Yang, S. R.
    Li, B. T.
    Riely, G. J.
    Offin, M.
    Yu, H. A.
    Kris, M. G.
    Drilon, A. E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S354 - S354
  • [6] RET FUSION-POSITIVE ADVANCED LUNG CANCERS: RESPONSE TO FIRST-LINE CHEMOTHERAPY AND SURVIVAL IN COMPARISON TO ROS1 AND ALK FUSION-POSITIVE AND EGFR- AND KRAS-MUTANT LUNG CANCERS
    Drilon, Alexander
    Wang, Lu
    Joubert, Philippe
    Snyder, Alexandra
    Cho, Eun Jung
    Riely, Gregory
    Kris, Mark
    Ladanyi, Marc
    Rizvi, Naiyer
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S902 - S903
  • [7] Frequency and Outcomes of Leptomeningeal Metastases in Patients with Fusion-Positive Lung Cancers
    Chen, M.
    Sui, J.
    Wilcox, J.
    Yang, S. R.
    Imber, B.
    Offin, M.
    Yu, H.
    Kris, M. G.
    Drilon, A. E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S677 - S677
  • [8] Activity of selpercatinib in RET fusion-positive cancers confirmed
    Diana Romero
    [J]. Nature Reviews Clinical Oncology, 2022, 19 : 747 - 747
  • [9] Activity of selpercatinib in RET fusion-positive cancers confirmed
    Romero, Diana
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2022, 19 (12) : 747 - 747
  • [10] Larotrectinib in TRK fusion-positive cancers
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2018, 19 (04): : E187 - E187
12345